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Abstract
Background: To build capacity in medicines management, the Uganda Ministry of Health introduced a nationwide
supervision, performance assessment and recognition strategy (SPARS) in 2012. Medicines management supervisors
(MMS) assess performance using 25 indicators to identify problems, focus supervision, and monitor improvement in
medicines stock and storage management, ordering and reporting, and prescribing and dispensing. Although the
indicators are well-recognized and used internationally, little was known about the reliability of these indicators. An
initial assessment of inter-rater reliability (IRR), which measures agreement among raters (i.e., MMS), showed poor IRR;
subsequently, we implemented efforts to improve IRR. The aim of this study was to assess IRR for SPARS indicators at
two subsequent time points to determine whether IRR increased following efforts to improve reproducibility.
Methods: IRR was assessed in 2011 and again after efforts to improve IRR in 2012 and 2013. Efforts included targeted
training, providing detailed guidelines and job aids, and refining indicator definitions and response categories. In the
assessments, teams of three MMS measured 24 SPARS indicators in 26 facilities. We calculated IRR as a team agreement
score (i.e., percent of the MMS teams in which all three MMS had the same score). Two sample tests for proportions
were used to compare IRR scores for each indicator, domain, and overall for the initial assessment and the following
two assessments. We also compared the IRR scores for indicators classified as simple (binary) versus complex
(multi-component). Logistic regression was used to identify supervisor group characteristics associated with
domain-specific and overall IRR scores.
Results: Initially only five (21%) indicators had acceptable reproducibility, defined as an IRR score≥ 75%. At the initial
assessment, prescribing quality indicators had the lowest and stock management indicators had the highest IRR. By the
third IRR assessment, 12 (50%) indicators had acceptable reproducibility, and the overall IRR score improved from 57%
to 72%. The IRR of simple indicators was consistently higher than that of complex indicators in the three assessment
periods. We found no correlation between IRR scores and MMS experience or professional background.
Conclusions: Assessments of indicator reproducibility are needed to improve IRR. Using simple indicators is recommended.
Keywords: Data reproducibility, Inter-rater reliability, IRR, Medicines management indicators, Data quality audit, Performance
assessment quality, Simple indicators, Complex indicators
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Background
Like many other developing countries, Uganda faces
serious financial and human resource constraints in the
health sector [1]. For every 100,000 citizens, there are
only 1.6 pharmacists; only 8% of public sector pharma-
cist posts and 61% of pharmacy technician posts were
filled in 2013/14 [2]. Because of the inadequate number
of pharmacy professionals, health workers from different
cadres are often called on to perform tasks related to
medicines management in their facilities despite their
lack of appropriate training [2]. This results in problems
that negatively affect service delivery (e.g., drug stock-
outs) and waste limited resources through inappropriate
management. Surveys in public sector facilities depict a
challenging environment; in 2010, less than 10% of
facilities had all six vital tracer medicines available, no
facilities had correctly filled stock cards, and only 1% of
facilities provided the correct treatment for a simple
cough and cold [3, 4]. The Ministry of Health’s traditional
approach of providing short training courses to address
the knowledge and skills gap in medicines manage-
ment has not produced significant or sustainable
improvements [3, 5].
Using multi-pronged approaches to build capacity and
change behaviors has proven to be more effective
compared to single approaches [6, 7], and in 2012,
following pilot results, Uganda’s Ministry of Health
introduced a new national multi-pronged approach to
build health worker capacity—the supervision, perform-
ance assessment and recognition strategy (SPARS). SPARS
combines supervision—in the form of “supportive super-
vision”—with performance assessment to identify problem
areas, guide supervision, and track improvements. A
recognition strategy rewards good performance. Selected
district health facility staff members trained as medicines
management supervisors (MMS) are tasked to build
capacity at health facilities by implementing SPARS [8].
The MMS assess medicines management performance
in five SPARS domains: 1) stock management, 2) storage
management, 3) dispensing, 4) prescribing, and 5)
ordering and reporting quality. They use a standardized
indicator-based assessment tool that includes 25 indi-
cators. The SPARS indicators in the five domains are
listed in Table 1. As part of their training, the MMS
receive an orientation on how to use the tool that
includes the indicators’ background and purpose; data
sources and data collection method; and indicator
calculation, analysis, and interpretation. MMS gather
indicator data during each supervisory visit by inter-
viewing exiting patients, observing health workers’
practices, and auditing records; the data gathering
method used depends on the indicator. They receive
netbooks and internet modems to facilitate data entry,
analysis, and reporting [8].
The SPARS facility assessment data are reported upward
to district health offices and national program managers
through a computerized national pharmaceutical manage-
ment information system. High-performing health facil-
ities, district health officers, and MMS are recognized
with rewards such as mobile phone air and modem time,
T-shirts, tea, calendars, soap, branded wall clocks, and
mugs. Since SPARS started piloting at the end of 2010,
MMS have submitted more than 12,000 SPARS facility
reports. Using medicines management performance data,
managers can identify problems more quickly and make
data-informed decisions. Facilities supervised to date have
documented improvements in medicines management [9].
Many indicators have been developed to assess various
aspects of medicines management and pharmaceutical
sector performance, and country programs use indicators
to identify problems and monitor progress [10, 11]. Too
often, however, programs apply well-known and well-
tested indicators, such as the World Health Organization
rational drug use indicators, without assessing the quality
of data or indicator reproducibility or investing the time
and effort needed to assure that the standards of data
collection and interpretation are met [10, 12, 13].
To ensure data quality and reproducibility of indicator-
based tools, it is important that the data collector has
enough training and practice to develop a sufficient un-
derstanding of what the indicators are measuring and how
to use them [10, 14, 15]. Data reliability is a critical issue,
especially when data are used to make program and policy
decisions. Suggested strategies to improve data quality in-
clude inter-rater reliability (IRR) assessments that measure
agreement among independent raters about their rating of
a characteristic or behavior plus efforts to improve IRR, if
it is insufficient [16–18].
From the outset, the Ministry of Health’s Pharmacy
Department prioritized efforts to assure data reliability,
because the SPARS data would be used to make
programmatic and policy decisions for the sector. The
Ministry of Health uses the SPARS facility scores to
implement a performance and certification program;
therefore, it is critically important that the SPARS scores
are reliable and independent of the rater (MMS) asses-
sing the performance.
As part of the development of the SPARS facility
assessment tool, we carried out a small exploratory study
in July 2011 to assess IRR of the SPARS indicators. The
low IRR scores in this initial assessment led to targeted
efforts to increase IRR. The research question for the
current study was to assess IRR for SPARS indicators
and to evaluate if targeted interventions improved inter-
rater reliability. The study objectives were to assess IRR
for 24 SPARS indicators collected by well-trained MMS
at three different time points and to examine whether
IRR increased after efforts to improve reproducibility,
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Table 1 List of the 25 SPARS indicators by the five domains
Dispensing quality Description
1. Dispensing time* Measures active/interactive dispensing time for 6 patients. Excludes any interruptions and time
spent on communication unrelated to the patient condition or medication
2. Packaging material Measures availability of appropriate dispensing materials like envelopes for solid dosage forms
and bottles for liquid dosage forms. Paper cones and reused bottles were considered
inappropriate
3. Dispensing equipment Measures availability of dispensing equipment for both liquid and solid dosage forms like
spoon, spatula, measuring cylinder, tablet counting tray to ensure that tablets are not counted
by bare hands
4. Services available at the dispensing area Measures access to privacy, chairs and benches, hand washing facilities at the facility and
drinking water for patients within the dispensing area
5. Patient care* Measures discrepancy between dispensed and prescribed medications and adequacy of
information provided to patients at dispensing (dose, frequency, duration, why to take and
other information required for adherence to medication)
6. Labeling* Measures adequacy of information on the label (medicines name, strength, quantity, date,
dose, name of patient and facility)
7. Rationing of antibiotics Measures the practice of rationing antibiotics when in short supply. Antibiotic quantities
prescribed and dispensed for 5 patients are compared to establish rationing, using amoxicillin
and cotrimoxazole as examples
Prescribing quality Description
8. Correct use of prescription recording system Measures appropriate recording of 10 prescriptions dispensed (date, OPD/IP number,
diagnosis, medicine and prescribers’ name, quantity of medicine prescribed and dispensed)
9. Rational prescribing* This standard World Health Organization indicator measures appropriate prescribing medicines
in 20 prescriptions, assessing average number of medicines prescribed per patient, percent of
products prescribed as generics, percent of prescriptions containing antibiotics, percent of
prescriptions containing injections, and percent of prescriptions with diagnosis recorded
10. Adherence to STG for diarrhoea Measures adherence to STG for non-bloody diarrhoea treatment. Appropriate treatment is ORS
and zinc only
11. Adherence to STG for common cough/cold
(simple respiratory tract infection)
Measures adherence to STG for cough/ cold. Appropriate treatment is optional antipyretic/
analgesic without use of antibiotics
12. Adherence to STG for malaria Measures adherence to STG for treatment of non-complicated malaria. Appropriate treatment
with antimalarials only should always follow a positive test
Stock management Description
13. Availability of stock card Measures availability of stock cards based on basket of 15 stock items
14. Correct filling of stock card Measures correct filling of stock cards (medicines name, strength, dosage form, average
monthly consumption, special storage conditions)
15. Does physical count agree with recorded
stock card balance
Measures whether stock balance according to stock card agrees with counted physical stock
16. Stock book** correctly used Measures correct use of stock book (all column information is appropriately filled and
calculated, including average monthly consumption and quantity to order)
Storage management Description
17. Cleanliness of the pharmacy Measures cleanliness of the dispensary and main store (floor, wall, shelves and medicines are
checked)
18. Hygiene of the pharmacy Measures availability, functionality, and hygiene of designated sanitary facilities for dispensary
staff (toilet, toilet paper, hand washing and soap).
19. System for storage of medicines and supplies Measures if medicines in the facility are stored on shelves/cupboards in an appropriate and
systematic manner and the shelves are labelled
20. Storage conditions (main store) Measures appropriate physical storage conditions and steps taken to assure quality and safety
of medicines in storage (sign of pest, protection from light, temperature monitoring and
regulation, roof condition, storage space, lockable storage, fire safety equipment, cold storage,
separate storing of medicines/vaccines appropriately in refrigerator, recording temperature in
refrigerator)
21. Storage practices of medicines in pharmacy
(stores & dispensary)
Measures adherence to good storage practices (incorrect storage on the floor, expired items
recorded and stored separately, FEFO, opened bottles labelled with opening date, and lids on
all containers)
Ordering and reporting Description
Blick et al. Journal of Pharmaceutical Policy and Practice  (2018) 11:11 Page 3 of 12
which included revisions of the tool, development of
guidelines, and additional MMS training.
Methods
MMS selection
To assess IRR, we used teams composed of three MMS
each. The MMS who participated in the IRR assessments
were randomly selected from the pool of all active MMS
at the time of the study. In the first assessment, 54
MMS were active, which increased to 151 by the second
assessment, and 224 by the third assessment. The active
MMS were grouped into “experienced” or “less expe-
rienced” based on the number of SPARS facility
assessments that the MMS had completed prior to
the IRR assessment. At the initial assessment, the
threshold for MMS to be considered experienced was
seven or more SPARS facility assessments; this
threshold increased to ≥12 visits in the following two
assessments because MMS had more time to
complete additional visits and thereby gain experi-
ence. In all three assessments, the MMS were ran-
domly selected from the two different experience
groups to make up rater teams with two experienced
MMS and one less-experienced MMS. The initial
assessment included only two rater teams, which
increased to 10 rater teams per assessment in the
second and third assessments. A total of 66 MMS
participated.
The three IRR assessments
The initial IRR assessment in July 2011 was conducted
to determine baseline IRR. The second (March–June
2012) and third (February–April 2013) IRR assessments
were specifically designed and carried out to evaluate
whether the revision of the tool, new guidelines, and
additional MMS training had contributed to improved
IRR scores. In the initial assessment, the two MMS teams
each assessed three facilities (six facilities total). In the two
following assessments, the 10 teams each assessed two
facilities, and each facility was assessed by two teams,
totaling 26 facilities in all three assessments (Table 2).
We selected the facilities purposefully to consider
accessibility from the facilities the MMS had planned to
supervise. The initial baseline assessment included two
higher level facilities. The next two assessments only in-
cluded lower level facilities, which are higher in number
(93%) and only have one medicine store, making it faster
to collect data for stock management indicators.
Data collection
When the MMS team visited a facility, each team member
independently collected the data needed and scored the
SPARS indicators using the standardized SPARS data
collection tool and method (Additional files 1 and 2). One
SPARS indicator (#23) was excluded from the assessment
because it only applied to higher-level facilities. A study
investigator oversaw each assessment to ensure that the
MMS did not communicate with each other during the
SPARS data collection. The investigator did not influence
or interfere in the data collection. We recorded the char-
acteristics of MMS teams to explore possible relationships
of IRR scores and rater team composition, including
gender, profession, and experience.
The MMS did not receive additional training or
orientation on the purpose of the study prior to the
IRR assessment. For SPARS indicators that required
record sampling (e.g., outpatient register records and
dispensing log), the investigator pre-selected the re-
cords to be used by all team members. Patient exit
interviews were conducted with the same patient; one
MMS conducted the interview, but all MMS recorded
their assessments independently. MMS assessed dispens-
ing time for the same patients, but individually. In the
stores, MMS observed the storage conditions and
collected stock management and ordering and reporting
information individually as per their basic MMS training.
Once each MMS independently completed the assess-
ment at the health facility using the SPARS tool, the
study investigator collected the tools and compiled the
scores from each MMS for each indicator in an Excel
spreadsheet. For the purpose of the IRR analysis, we
classified the 24 SPARS indicators into two groups based
on their complexity (Table 3). Simple indicators are
Table 1 List of the 25 SPARS indicators by the five domains (Continued)
Dispensing quality Description
22. Reorder level calculation Measures ability of the facility to correctly calculate reorder quantity
23. Timeliness of order & distribution*** Measures adherence to order and delivery schedules (only applicable for higher level facilities)
24. Accuracy of HMIS reports Measures if the health facility staff update the HMIS 105 report with accurate information on
medicines availability during the previous month from stock management records. Stock card
and HMIS 105 information are compared for consistency for a basket of 6 EMHS.
25. Filing Measures appropriate filing of previous orders, delivery notes and discrepancy reports
Notes: OPD=outpatient department; IP=inpatient; ORS=oral rehydration solution; STG=standard treatment guidelines; FEFO=First expiry first out; HMIS=Health
Management Information System; EMHS=essential medicines and health supplies
*World Health Organization indicators or sub indicators; **Stock book summarize in one line the monthly transactions from the stock card ***Excluded from
assessment
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those that require binary yes or no answers, and complex
indicators are composites with sub-indicators that
require sampling and calculations.
Scoring
We looked at the SPARS scores to assess agreement
across the three-person team (i.e., team agreement
score) to calculate an IRR score for each indicator. We
used a slightly different approach to assess team agree-
ment score depending on the type of indicator:
 For yes or no responses, the team agreement score
was 100% if all the three MMS agreed; otherwise,
it was 0% [18].
 In a continuous scale, a team agreement score of
100% was given if all three MMS had a SPARS score
within +/− 10% of the median value for the group.
If not, the team agreement score was 0%.
 For the indicator dispensing time, a team agreement
score of 100% was given if all three MMS assessed
the average dispensing time for the patients
within +/− 15 s of the median value for the group.
If not, the IRR score was 0%.
For indicators that had sub-questions or sub-indicators,
the team agreement score was separately assessed for each
sub-question and then averaged across the sub-questions
for that indicator. We calculated the average percentage
agreement across all MMS teams to measure the IRR for
an indicator (i.e., the proportion of teams that scored
100%). An illustration of the IRR score calculation for
indicators, sub-indicators, and domains is provided
(Additional file 3).
Inter-rater reliability was deemed “acceptable” if the IRR
score was ≥75%, following a rule of thumb for acceptable
reliability [19]. IRR scores between 50% and < 75% were
considered to be moderately acceptable and those < 50%
were considered to be unacceptable in this analysis.
Statistical analysis
For each of the three IRR assessment periods, we
calculated the average IRR for each of the 24 indicators,
indicator category (simple or complex), the five SPARS
domains and overall SPARS score and compared the IRR
scores of the three IRR assessment periods using a
two-sample test for proportions.
To determine whether there was an association be-
tween MMS group characteristics and SPARS reliability,
we used logistic regression to estimate the odds ratio
and the 95% CI associated with having a score of ≥75%
for each SPARS domain by MMS team composition
type. The MMS team composition characteristics that
we assessed were gender (i.e., number of males on the
team), profession, and experience based on the average
number of SPARS visits carried out by the team prior to
the IRR assessment. All these analyses were conducted
using STATA, Version 13 and Excel 2007.
Efforts to improve measurement reliability
Prior to making SPARS a national strategy, we piloted
the performance assessment tool with simple instruc-
tions over 12 months and made several adjustments dur-
ing that time. In 2010 the tool was finalized for national
rollout and became the basis for the MMS two-week
classroom training and five-day practical training.
In July 2011, we carried out the first exploratory IRR as-
sessment, and although the sample was small, the findings
led to the development of training programs to increase
IRR scores (Table 2). We then applied interventions that
are proven to be effective in increasing reliability [20]. To
Table 3 Classification of SPARS indicators by complexity
Simple indicators (13/24) Complex indicators (11/24)
2. Packaging material
3. Dispensing equipment
4. Services available at dispensing
areas
7. Rationing of antibiotics
13. Availability of stock card
14. Correct filling of stock card
16. Stock book correctly used
17. Pharmacy cleanliness
18. Pharmacy hygiene
19. Storage system for medicines
and supplies
20. Storage conditions






8. Correct use of prescription
recording system
9. Rational prescribing
10. Adherence to STG for diarrhea
11. Adherence to STG for
cough/cold
12. Adherence to STG for malaria
15. Physical count agrees with
stock card balance
22. Reorder level calculation
24. Accuracy of HMIS reports
Table 2 Summary of efforts to improve reproducibility and IRR assessments
Efforts flow Timing Number of MMS rater
teams (total # of MMS)
# IRR facility assessments
by each team
Total # of IRR
assessments
# facilities by level
of care (High/Low)
IRR assessment: 1 Jul 2011 2 (6) 3 6 2 High, 4 Low
Effort: 1 Jan 2012 All MMS receive effort 1
IRR assessment: 2 Mar-Jun 2012 10 (30) 2 20 10 Low
Effort 2 Sep 2012 All MMS receive effort 2
IRR assessment: 3 Feb-Apr 2013 10 (30) 2 20 10 Low
Total Jul 2011-Apr 2013 22 (66) Not applicable 46 2 High, 24 Low
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increase IRR by reducing errors in measurement proce-
dures and interpretation, we developed guidelines, refined
indicator wording and definitions in the tool to increase
clarity, and re-trained MMS in the problematic indicators
identified by the IRR assessments (< 75% IRR score).
Starting in January 2012, detailed data collection
guidelines were developed to supplement the simple in-
structions. We now included in the data collection tool
descriptive information on each indicator that had been
highlighted during training, including information on
the background, purpose, and operational definitions of
indicators, and guidelines on methods to collect, analyze,
and interpret data. Some indicator response categories
were simplified to make MMS assessment more straight-
forward; for example, cleanliness of dispensary and main
store was revised from the possible response categories—
very clean/tidy (score 1), acceptable clean/tidy (score 0.5),
and not clean/untidy (score 0), to only two categories:
clean/tidy (score 1) and not clean/untidy (score 0). For
other indicators, MMS were given examples of what they
should look for in their assessment, for example for pres-
ence of pests in the store, we advised them to check for
wasp nests, cobwebs on the ceilings, termites along the
walls, and small droppings of bats or rats. These efforts
were followed by the second IRR assessment in March–
June 2012 (Table 2).
In September 2012, we issued a second revision of the
tool and guidelines that further clarified challenging
indicators. The final SPARS data collection guidelines
are provided in Additional file 2. After the introduction
of the revised tool, all MMS attended a targeted two-day
training course that focused on the problematic indica-
tors and other frequent errors. We focused heavily on
the complex indicators that involve several steps,
including multiple calculations, to produce the SPARS
indicator score and the correct use of zero and “not
applicable” and how to address blank fields. To test
individual MMS’ understanding of the focus indicators,
we incorporated practical exercises using multiple choice
questions. An example of such an exercise is given in
Fig. 1. The group would discuss the answers to achieve a
common understanding.
We realized that MMS’ calculation skills differed con-
siderably because they come from diverse health-related
professional backgrounds, and that we needed to con-
sider this in the training design. Consequently, we added
more test examples to give them ample practice. We
refined the standard operating procedures for SPARS
data management to clarify information on tracking fa-
cility visits, data cleaning, data security, and reporting.
The September 2012 revision and training were followed
by the third and final IRR assessment in February–April
2013 (Table 2). To reduce errors, we also shifted from a
manual tool to an electronic tool that automatically
calculates the scores for some of the indicators. How-
ever, the electronic SPARS data collection was not rolled
out until December 2013, after the study period.
Ethical considerations
This study evaluated IRR of medicines management data
as part of the national capacity-building strategy SPARS
carried out by MMS under the Ministry of Health,
Uganda. The study did not involve patients, human or
personal health data, human tissue, or animals. There-
fore, the study did not require ethical approval or a wai-
ver. All observations and data collection were conducted
with the permission of Ministry of Health, the District
Health Officers, the facility in-charges, and the MMS.
The study constituted a Ministry of Health initiated
data quality evaluation and is approved by the Ministry
of Health.
Results
Table 4 presents the average IRR scores for the 24
indicators, the two indicator categories, the five
domains, and overall scores from each of the three IRR
assessments. The IRR scores for the rational drug use
sub-indicators are presented in Additional file 4.
I. Overall IRR score (all 24 indicators)
The overall IRR score across all indicators improved
from 57% in 2011 to 72% in 2013. The number of indi-
cators with an acceptable IRR score (≥75%) increased
from five indicators (21% of the 24 indicators) in 2011 to
12 indicators (50% of the indicators) in 2013.
Of the 24 indicators, the IRR scores of 17 (71%)
improved between the initial and third assessments. The
average IRR indicator improvement for the 17 indicators
was 24 percentage points (range: 4%–68%). The IRR
scores for seven indicators got worse between the first
and third assessment with an average reduction of 11%
points (range: − 2% to − 25%) (Table 4). The number of
indicators with unacceptable IRR scores (i.e., IRR < 50%)
fell from seven to only one following the two interven-
tions (Fig. 2). Figure 3 depicts the IRR scores for each
indicator presented by domains at the first and third
assessments. Between the first and third assessment the
IRR score ranges narrowed with more indicators having
an IRR score of 75%, indicating improvement in repro-
ducibility and data quality over the study period from
2011 to 2013.
II. IRR scores for indicator and domains
Dispensing quality
Two indicators in this domain, packaging material and
labelling, had an acceptable IRR score of ≥75% at all
three assessments. Three additional indicators had an
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acceptable reproducibility score at the third intervention
(not significant improvement): dispensing equipment,
services available at dispensing area, and no discrepancy
between prescribed and dispensed medicine—cotrimoxa-
zole/amoxicillin. Two indicators, dispensing time and
patient care, were below the acceptable reproducibility
score by more than 10 percentage points at the final
assessment. The overall IRR score for the dispensing
domain at the third assessment was acceptable (76%).
Prescribing quality
Of the five indicators in this domain, only one, rational
prescribing, had acceptable reproducibility at only the
second assessment, after improving significantly from
the first to second assessment (p = 0.038). Three indica-
tors, correct use of recording system, rational prescribing,
and adherence to treatment guidelines for malaria, im-
proved considerably between the first and third assess-
ments (not significant), but did not reach the acceptable
reproducibility benchmark. Overall, the prescribing
quality domain IRR score improved but remained not
acceptable at the final assessment (64%).
Stock management
Three of the four indicators, availability of stock card,
agreement between stock card and physical count and
stock book filled correctly, had acceptable reproducibility
scores at the third assessments, although the IRR for the
latter two declined over time (not significant). One indi-
cator, availability of stock card, improved significantly
from the first to the third assessment (p = 0.002). Correct
filling of stock card continued to be difficult to assess in
a unified manner and had a low IRR score despite our
efforts to improve IRR. Overall, however, the stock
management domain IRR score was acceptable at the
final assessment (76%).
Storage management
One indicator in this domain, storage conditions, had an
acceptable reproducibility score at all three assessments.
By the third assessment, two other indicators also
achieved an acceptable reproducibility score: hygiene of
the pharmacy and systems of storage. One indicator,
cleanliness of the pharmacy, had the largest improve-
ment between the first and third assessments (not sig-
nificant) but with an IRR score far below the acceptable
reproducibility threshold of ≥75%. The overall IRR score
for the storage domain remained just below the accept-
able threshold (73%).
Ordering and reporting
Of the three indicators in this domain, one—reorder
level calculation—achieved an acceptable IRR score by
the third assessment with a significant improvement be-
tween the first and third assessment (p = 0.001). Accuracy
of the health management information system (HMIS) re-
port declined from moderately acceptable reproducibility
to unacceptable (not significant). The domain IRR score
improved following the interventions, but remained just
below the acceptable threshold of ≥75% (70%).
III. IRR scores for simple or complex indicator categories
In the initial assessment, neither of the two indicator
categories, simple or complex, had an acceptable IRR
score. IRR scores improved following two assessments
for both categories, with the simple indicators improving
by 15 percentage points between the initial and third as-
sessments (p = 0.475) and complex indicators improving
by 13 percentage points (p = 0.558).
Fig. 1 Example of SPARS indicator exercise from the MMS training
Blick et al. Journal of Pharmaceutical Policy and Practice  (2018) 11:11 Page 7 of 12
Table 4 Average IRR scores (%) for 24 SPARS indicators and tests of change, by domain and indicator category
Assessment Assessments
1 2 3 1 to 2 2 to 3 1 to 3
Number of teams (facilities assessed by each team) 2 (3) 10 (2) 10 (2)
Number of assessments n=6 n=20 n=20 iwo sample test lor proportions
Dispensing quality domain
1. Dispensing time 67 55 60 0.602 0.749 0.757
2. Packaging material 83 100 100 0.060 - 0.060
3. Dispensing equipment 71 90 80 0.245 0.376 0.641
4. Services available at dispensing area 67 81 78 0.470 0.814 0.583
5. Patient care 37 72 64 0.117 0.588 0.240
6. Labeling 79 83 75 0.823 0.535 0.841
7. No discrepancy between prescribed and dispensed
medicines cotrimoxazole/ amoxicillin- Rational prescribing
50 45 75 0.829 0.053 0.245
Dispensing quality domain 65 75 76 0.630 0.941 0.593
Prescribing quality domain
8. Correct use of prescription recording system 33 65 70 0.164 0.736 0.102
9. Rational Prescribing 30 76 63 0.038 0.372 0.154
10. Adherence to standard treatment guidelines diarrhea 67 60 60 0.757 1.000 0.310
11. Adherence to standard treatment guidelines cough and cold 67 45 65 0.345 0.204 0.928
12. Adherence to standard treatment guidelines malaria 25 65 63 0.084 0.895 0.101
Prescribing quality domain 44 62 64 0.434 0.896 0.382
Sto ck management do main
13. Availability of stock card/ledger book 17 55 85 0.102 0.038 0.002
14. Correct filling of stock card 50 50 55 1.000 0.752 0.829
15. Does physical count agree with stock card 100 75 90 0.173 0.212 0.420
16. Stock book correctly filled 100 95 75 0.576 0.077 0.173
Sto ck management do main 67 69 76 0.926 0.62 0.66
Storage management domain
17. Cleanliness of the pharmacy 33 40 55 0.757 0.342 0.345
18. Hygiene of the pharmacy 57 77 75 0.337 0.882 0.395
19. System of storage of medicines and supplies 63 84 79 0.267 0.684 0.425
20. Storage conditions 79 88 88 0.578 1.000 0.578
21. Storage practices of medicines in pharmacy (stores and dispensary) 64 77 68 0.524 0.524 0.855
Storage management domain 59 73 73 0.513 1.00 0.513
Ordering and reporting domain
22. Reorder level calculation 33 50 95 0.464 0.001 0.001
24. Accuracy of HMIS report 67 70 45 0.889 0.110 0.345
25. Filing 50 45 70 0.829 0.110 0.366
Ordering and reporting domain 50 55 70 0.829 0.327 0.366
Overall Score 57 67 72 0.653 0.731 0.488
Indicator categories
Complex 55 65 68 0.657 0.841 0.558
Simple 60 71 75 0.611 0.776 0.475
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The complex category did not reach the ≥75% thresh-
old of acceptable reproducibility by the third assessment,
however, the simple indicator category just reached the
75% cut-off (Fig. 3).
IV. IRR scores and rater (MMS) team characteristics
We found no statistically significant relationship between
the IRR scores and any of the characteristics of the MMS
raters—gender, profession (e.g., clinical officer), or average
number of prior SPARS supervisory visits completed
(Additional file 5).
Discussion
This study measured IRR for the 24 SPARS medicines
management indicators used to assess performance in
the Ugandan pharmaceutical sector at three different
time points and examined whether IRR increased after
efforts to improve reproducibility. The SPARS data
collection tool uses well-known indicators, the tool was
thoroughly piloted, and the MMS received three weeks
of combined classroom and practical training. Despite
this preparation, we found that initially the MMS’ IRR
scores for the medicines management indicators in the
SPARS assessment was poor; only five of the 24 indica-
tors achieved an acceptable IRR of ≥75%. Our findings
highlight the fact that IRR must be considered when
designing indicator-based assessments, even when using
well-known and globally recognized indicators and
extensively trained data collectors.
Pharmaceutical sector indicators that assess rational
drug use and supply chain performance are used to
guide policies and system change [10, 11, 14]. These in-
dicators are widely accepted as an objective and standard
measure of rational use of medicines and medicines
management and have been used in more than 30
mainly developing countries [21]. However, very few
programs make the effort to assess the temporal and
inter-rater reliability of the indicators they use. Therefore,
little is known about the reproducibility of pharmaceutical
sector indicators [13]. A systematic literature review of the
use of medicine-related indicators in Southeast Asia found
little information on validity, reliability, and feasibility of
these indicators, especially those not promoted by World
Health Organization [13]. The World Health Organization
drug use indicators have been developed using appropriate
methods, tested in numerous countries, applied in a
standardized way in many studies and are widely
Fig. 2 Distribution of indicators by IRR score, at first, second, and
third assessments
Fig. 3 Inter-rater reliability scores for 24 SPARS indicators and complex & simple indicator types at first and third assessments for 2011–2013.
*Optimal IRR score is 100%, acceptable score of ≥75% marked with red line and 50% marked with black line
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accepted [10, 13, 22, 23]. Nevertheless, we found that
both World Health Organization and non- World Health
Organization indicators had poor inter-rater reliability.
Our study is one of the first that measures and documents
the IRR of pharmaceutical and rational drug use indi-
cators. Moreover, we suggest multi-pronged interven-
tions to increase IRR of problematic pharmaceutical
sector indicators.
This study suggests that focused and practical training
and tailored instructions may improve IRR scores for
pharmaceutical and medicines management indicators; at
the final assessment half (12) of the 24 indicators achieved
an acceptable ≥75% IRR and only one had an IRR of less
than 50%. IRR of indicators in all five domains improved
following the interventions, reaching acceptable or almost
acceptable scores; only the prescribing quality domain in-
dicators continued to have low IRR. Both the IRR and the
effectiveness of our efforts to improve IRR depended
greatly on the type of indicator. Not surprisingly, indica-
tors that involve complex calculations, detailed sampling,
and a high degree of judgement required the most effort
to achieve acceptable reliability. Prescribing domain
indicators are all complex indicators and have very specific
data collection methods. The MMS were trained in sam-
pling and the complicated calculations; however, correctly
assessing these complex indicators remained a challenge
for many MMS, even with extra attention. Therefore,
although the domain had the highest improvement in IRR
score overall, it remained the domain with the lowest
reproducibility in scores.
Despite overall improvement, the IRR score did not
improve for all SPARS indicators. IRR for two indicators
decreased by over 20 percentage points: stock book is
filled in correctly and accuracy of the HMIS report. At
the time of the first assessment in 2011, most facilities
had not yet received the new stock book, and the indica-
tor could therefore only be scored “not applicable.” Later
when all the facilities received stock books, the MMS
needed to know how to fill in the stock book correctly
to assess the indicator, causing reproducibility to decline.
Each facility reports data on a monthly basis into a
centralized HMIS. The HMIS report includes data on
availability of a selected basket of medicines and health
supplies and patient attendance figures. A new HMIS
form was introduced to the health facilities at the end of
2012. Assessing accuracy of the data reported in the new
HMIS form is likely to have declined due to the intro-
duction of the new HMIS form without related training
for the MMS.
This study has multiple limitations. Although the
overall IRR score increased over the three assessments,
we cannot attribute the improvement to the revised tool
and training because we did not use a controlled design;
other changes, such as MMS gaining more experience
over time, changes in the MMS used as raters, or
changes in the sample of facilities assessed could have
contributed to the improvement in the IRR scores.
MMS experience increased across assessments as they
made more visits, and the threshold for MMS to be con-
sidered experienced increased from ≥7 SPARS facility
visits initially to ≥12 SPARS visits in the last two assess-
ments. Though the composition of the assessment team
remained consistent with one less experienced and two
experienced MMS’s, the number of visits that comprised
the definition of “experienced” rose after the first assess-
ment; therefore, the teams became more experienced
overall. However, because we observed improvements in
both the second and third assessment with same thresh-
old for experience (≥12), the revised tool and training
likely contributed to reproducibility improvements.
The study is also limited by the small number of obser-
vations in the initial assessment, which resulted in insuffi-
cient power to detect statistically significant differences
between the three assessments. We included the initial
findings because they demonstrated the need to improve
IRR. We limited the later assessments to lower level facil-
ities because they manage fewer pharmaceutical products
than higher level facilities and have only one medicines
storage area, which shortens the time MMS need to col-
lect the SPARS data and allows more time for supportive
supervision; lower level facilities also constitute 93% of all
public sector health facilities.
We chose to measure IRR using percentage agreement
instead of Fleiss kappa coefficient, which measures inter-
rater agreement among three raters, because we did not
have a sufficient number of facilities per MMS team to
calculate kappa [18, 24]. Compared to other IRR methods,
the percentage agreement approach tends to overestimate
IRR due to chance agreement. However, our method was
conservative, requiring agreement among three raters in-
stead of the more commonly used agreement between
two raters. Finally, we did not assess the validity of the in-
dicators because we did not have a gold standard.
Measuring performance using the SPARS indicators has
been proven to be feasible and useful to identify medicines
management problems and to track the impact of SPARS
in health facilities in Uganda. Uganda now has in place a
strong capacity building strategy with indicators, training
approaches, and data collection methods that ensure re-
producible results for most of the indicators, not only for
guiding the supervision and tracking improvements, but
also for informing national pharmaceutical policy.
Conclusion
Health program managers must have access to reliable
information to identify problems, monitor progress
accurately, and make evidence-based decisions. Often
such information is obtained through indicator-based
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tools, but the reliability of these indicators is unknown.
By testing the IRR of the SPARS assessment indicators,
we identified problems in how supervisors understood
and calculated the indicators. Our study suggests that
targeted and multi-pronged efforts including training,
tool revisions, and repeated instructions can improve re-
producibility of the SPARS indicator ratings. We now
have a set of indicators with an average IRR score of
72%, just shy of the acceptable level, and three of five
domains that achieved an acceptable IRR of ≥75%. We
learned that, where possible, it is best to use simple bin-
ary indicators when designing an indicator-based assess-
ment tool and that assessing and improving IRR should
be an iterative process. Having uniform data reproduci-
bility standards, assessment methods, and guidelines for
best practices to evaluate IRR of indicators would make
it easier for more programs in resource-limited countries
to improve their data quality.
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